Rilotumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rilotumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target HGF
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6464H9932N1708O2010S46
Molar mass 145.2 kg/mol
 NYesY (what is this?)  (verify)

Rilotumumab (previously AMG102) is a human monoclonal antibody designed for the treatment of solid tumors.[1]

Rilotumumab was in development by Amgen, Inc. until in November 2014, when Amgen announced it had halted all clinical trials of the compound in advanced gastric cancer (including two Phase III studies) after one of the trials found an increase in the number of deaths in those who were taking rilotumumab and chemotherapy when compared to those who were only administered chemotherapy.[2][3]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab" (PDF). American Medical Association. 
  2. ^ "Amgen scraps trials of drug for advanced stomach cancer". yahoo.com. 24 Nov 2014. Retrieved 24 Nov 2014. 
  3. ^ http://www.genengnews.com/gen-news-highlights/amgen-halts-rilotumumab-trials-in-advanced-gastric-cancer/81250637/